Clinical Trials Logo
  1. Home
  2. Myeloma Multiple
  3. NCT05944783

Bioequivalence Studies of Dasatinib 100 mg — BE-Dasatinib  

Myeloma Multiple Clinical Trial

Official title:
Bioequivalence Studies of Dasatinib 100 mg Tablets in Healthy Colombian Subjects in Postprandial Condition

Clinical Trial Summary

A bioequivalence study of Dasatinib will be carried out in 46 healthy subjects, in fed condition, following the complete replicated design, randomized, comparative of 2 sequences, 2 study formulations, in a single dose of 100 mg of Dasatinib tablets / coated tablets, 4 periods. , with a washout time of 7 days between each dose

Clinical Trial Description

A bioequivalence study of Dasatinib in 46 healthy subjects, in fed condition, complete replicated design, comparative of 2 sequences, 2 formulations, single dose of 100 mg of Dasatinib tablets / coated tablets, 4 periods. , with a washout time of 7 days between each dose ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05944783
Study type Interventional
Source Centro de Atencion e Investigacion Medica
Contact
Status Not yet recruiting
Phase Phase 4
Start date November 1, 2023
Completion date January 30, 2024
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06205823 - Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM
Recruiting NCT04782687 - Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma Phase 2
Active, not recruiting NCT05889221 - Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma N/A
Recruiting NCT03891914 - Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma Phase 3
Recruiting NCT04268199 - A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment Phase 2
Not yet recruiting NCT06133426 - Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients N/A
Completed NCT05887206 - Corneal Toxicity in Patients Treated by Belantamab Mafodotin
Completed NCT04065789 - Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients Phase 2
Active, not recruiting NCT03089411 - Collection of Additional Data Followed the Study IFM 2013-04 N/A
Completed NCT04436029 - Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy Phase 2
Not yet recruiting NCT04364724 - CTFEA Myeloma Study
Recruiting NCT05932680 - Limited-duration Teclistamab Phase 2
Not yet recruiting NCT06418750 - Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot Study N/A
Completed NCT04236063 - Rehabilitation Needs of the Malaysian Haematological Cancer Survivors
Terminated NCT04242121 - The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood
Not yet recruiting NCT03607643 - A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies Phase 1/Phase 2
Recruiting NCT05651932 - A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma Phase 1
Not yet recruiting NCT06245629 - Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
Recruiting NCT03992170 - Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive Phase 2
Terminated NCT04843579 - Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients Phase 2